BioNTech Shares Surge on Positive Phase 3 Lung Cancer Trial Data

BioNTech shares (ticker: BNTX) surged in pre-market trading after the company and its partner, OncoC4, announced significantly positive updated results from a Phase 3 trial for their experimental lung cancer therapy, gotistobart.

Promising Trial Data

The updated results from the PRESERVE-003 trial were presented at the IASLC 2026 World Conference on Lung Cancer. The study focuses on patients with previously treated squamous non-small cell lung cancer (NSCLC), a population with historically poor prognoses.

The data, concurrently published in the peer-reviewed journal *Nature Medicine*, showed a substantial improvement in patient outcomes:

• Median Overall Survival: The trial demonstrated a median overall survival of 18.5 months for patients treated with gotistobart, compared to just 10.0 months for those receiving standard-of-care docetaxel chemotherapy.
• Reduced Risk of Death: The findings corresponded to a hazard ratio of 0.56, indicating a statistically and clinically significant reduction in the risk of death for patients on gotistobart.

Market Reaction and Analyst Support

Ad

Investors responded favorably to the news, with BioNTech's stock climbing 5.6% in pre-open trading. The gain was particularly notable as it came against a backdrop of broad market weakness, with the S&P 500 and Nasdaq indices both trading lower.

Compounding the positive sentiment, analysts at Morgan Stanley reportedly initiated or reiterated a "Buy" rating on the stock, providing institutional validation for the data-driven rally.

Context and Next Steps

Squamous NSCLC represents a significant unmet medical need, accounting for roughly 25% to 30% of all lung cancer cases, where chemotherapy has been the standard second-line treatment for more than a decade. The strong survival data positions gotistobart as a potential new standard of care.

The pivotal Stage 2 portion of the PRESERVE-003 trial is currently enrolling patients across more than 160 sites globally. The company noted that Monday's results are a strong signal ahead of a final readout that could potentially support regulatory submissions for marketing approval.